Celldex Therapeutics [CLDX] vs Axsome Therapeutics [AXSM] Detailed Stock Comparison

Celldex Therapeutics Inc.

NASDAQ
Loading...

Axsome Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Celldex Therapeutics Inc. wins in 5 metrics, Axsome Therapeutics Inc. wins in 12 metrics, with 0 ties. Axsome Therapeutics Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Celldex Therapeutics Inc. Axsome Therapeutics Inc. Better
P/E Ratio (TTM) N/A -50.54 N/A
Price-to-Book Ratio 4.36 105.31 Celldex Therapeutics Inc.
Debt-to-Equity Ratio 0.44 247.03 Celldex Therapeutics Inc.
PEG Ratio -7.21 0.79 Axsome Therapeutics Inc.
EV/EBITDA -6.28 -57.70 Celldex Therapeutics Inc.
Profit Margin (TTM) 0.00% -28.69% Celldex Therapeutics Inc.
Operating Margin (TTM) -72,027.27% -18.38% Axsome Therapeutics Inc.
Return on Equity -40.62% -252.12% Celldex Therapeutics Inc.
Return on Assets (TTM) -26.12% -16.81% Axsome Therapeutics Inc.
Free Cash Flow (TTM) $-213.66M $-93.89M Axsome Therapeutics Inc.
1-Year Return 47.08% 145.12% Axsome Therapeutics Inc.
Price-to-Sales Ratio (TTM) 1,754.63 14.64 Axsome Therapeutics Inc.
Enterprise Value $1.78B $9.24B Axsome Therapeutics Inc.
EV/Revenue Ratio 1,154.45 14.47 Axsome Therapeutics Inc.
Gross Profit Margin (TTM) N/A 93.71% N/A
Revenue per Share (TTM) $0 $13 Axsome Therapeutics Inc.
Earnings per Share (Diluted) $-3.90 $-3.69 Axsome Therapeutics Inc.
Beta (Stock Volatility) 1.20 0.47 Axsome Therapeutics Inc.
Short % of Float 16.10% 6.56% Axsome Therapeutics Inc.

Celldex Therapeutics Inc. vs Axsome Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

CLDX
AXSM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Celldex Therapeutics Inc.2.72%12.46%2.49%6.39%18.57%18.92%
Axsome Therapeutics Inc.-0.69%7.77%11.28%60.15%73.28%41.81%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Celldex Therapeutics Inc.47.08%-12.36%12.56%-51.18%-34.03%-89.07%
Axsome Therapeutics Inc.145.12%200.20%278.87%3,924.76%2,713.34%2,713.34%

Performance & Financial Health Analysis: Celldex Therapeutics Inc. vs Axsome Therapeutics Inc.

MetricCLDXAXSM
Market Information
Market Cap i$2.69B$9.51B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i1,192,670592,425
90 Day Avg. Volume i1,198,533602,162
Last Close$32.12$253.40
52 Week Range$19.52 - $35.79$96.09 - $257.92
% from 52W High-10.25%-1.75%
All-Time High$3,375.00 (Mar 06, 2000)$257.94 (Jun 12, 2026)
% from All-Time High-99.05%-1.76%
Growth Metrics
Quarterly Revenue Growth-0.90%0.65%
Quarterly Earnings Growth-0.90%0.65%
Financial Health
Profit Margin (TTM) i0.00%-0.29%
Operating Margin (TTM) i-720.27%-0.18%
Return on Equity (TTM) i-0.41%-2.52%
Debt to Equity (MRQ) i0.44247.03
Cash & Liquidity
Book Value per Share (MRQ)$7.92$1.74
Cash per Share (MRQ)$7.79$6.31
Operating Cash Flow (TTM) i$-210,944,992$-93,405,000
Levered Free Cash Flow (TTM) i$-125,544,376$-29,420,876
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Celldex Therapeutics Inc. vs Axsome Therapeutics Inc.

MetricCLDX (Apr 22, 2026)AXSM (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/A-50.54
Forward P/E i-7.2129.85
PEG Ratio i-7.210.79
Price to Sales (TTM) i1,754.6314.64
Price to Book (MRQ) i4.36105.31
Market Capitalization
Market Capitalization i$2.69B$9.51B
Enterprise Value i$1.78B$9.24B
Enterprise Value Metrics
Enterprise to Revenue i1,154.4514.47
Enterprise to EBITDA i-6.28-57.70
Risk & Other Metrics
Beta i1.200.47
Book Value per Share (MRQ) i$7.92$1.74

Financial Statements Comparison: Celldex Therapeutics Inc. vs Axsome Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCLDX (2025)AXSM (2025)
Revenue/Sales i1.55M638.50M
Cost of Goods Sold iN/A47.48M
COGS % of Revenue i0.0%7.4%
Gross Profit iN/A591.02M
Gross Margin i0.0%92.6%
Research & Development i245.07M183.28M
Operating Income (EBIT) i-287.37M-169.24M
Operating Margin i-18,599.8%-26.5%
EBITDA i-312.60M-160.17M
EBITDA Margin i-20,232.8%-25.1%
Pre-Tax Income i-258.76M-183.70M
Pre-Tax Income % of Revenue i-16,748.0%-28.8%
Income Tax iN/A-530,000
Income Tax % of Revenue i0.0%-0.1%
Net Income (Profit) i-258.76M-183.17M
Profit Margin i-16,748.0%-28.7%

Balance Sheet & Liquidity Metrics

MetricCLDX (2025)AXSM (2025)
Cash & Equivalents i28.87M322.93M
Total Current Assets i534.66M588.99M
Total Current Assets % of Revenue i34,606.1%92.2%
Total Current Liabilities i50.99M378.84M
Total Current Liabilities % of Revenue i3,300.4%59.3%
Long-Term Debt i784,000145.13M
Long-Term Debt % of Revenue i50.7%22.7%
Total Shareholders Equity i527.17M88.30M
Retained Earnings i-1.81B-1.31B
Retained Earnings % of Revenue i-117,409.8%-204.5%
Property, Plant & Equipment i15.68M562,000

Cash Flow Statement Comparison

MetricCLDX (2025)AXSM (2025)
Operating Cash Flow i-224.84M-185.86M
Operating Cash Flow % of Revenue i-14,552.7%-29.1%
Capital Expenditures i-2.71M-480,000
Free Cash Flow i-213.66M-93.89M
FCF Margin i-13,829.1%-14.7%
Debt Repayment iN/A-334.11M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricCLDXAXSM
Shares Short i9.08M2.83M
Short Ratio i9.644.92
Short % of Float i16.10%6.56%
Shares Outstanding i66.55M50.88M
Float Shares i61.37M43.24M
% Held by Insiders i0.15%15.47%
% Held by Institutions i96.77%76.52%
% Held by Public i3.08%8.01%

Dividend Analysis & Yield Comparison: Celldex Therapeutics Inc. vs Axsome Therapeutics Inc.

MetricCLDXAXSM
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A